Wernicke S, Selleng K, Felix S B, Greinacher A, Hammer F
Klinik und Poliklinik für Innere Medizin B, Universitätsmedizin Greifswald, Ferdinand-Sauerbruch-Str., 17475, Greifswald, Deutschland.
Institut für Immunologie und Transfusionsmedizin, Universitätsmedizin Greifswald, Greifswald, Deutschland.
Internist (Berl). 2017 Jul;58(7):735-739. doi: 10.1007/s00108-017-0211-6.
We report on a female patient with confirmed secondary antiphospholipid syndrome (APS) due to underlying systemic lupus erythematosus (SLE). Despite a thromboplastin time within the normal range (international normalized ratio, INR) under treatment with a vitamin K antagonist (VKA), a recurrent thrombotic event occurred, this time as pulmonary embolism due to bilateral deep vein thrombosis. Despite an INR value in the therapeutic range, clotting factors II, VII, IX and X were found to be insufficiently decreased suggesting inefficient anticoagulation. Thus, the anticoagulation regimen was changed to the direct oral anticoagulant dabigatran. This case demonstrates that the INR in APS patients may be artificially prolonged in rare cases, despite a normal activated partial thromboplastin time (aPTT) and cannot be used for monitoring VKA anticoagulant therapy. Suspicion of ineffective anticoagulation despite VKA therapy should prompt measurement of the individual clotting factors.
我们报告了一名因潜在系统性红斑狼疮(SLE)确诊为继发性抗磷脂综合征(APS)的女性患者。尽管在使用维生素K拮抗剂(VKA)治疗期间凝血酶原时间在正常范围内(国际标准化比值,INR),但仍发生了复发性血栓事件,此次表现为双侧深静脉血栓形成导致的肺栓塞。尽管INR值在治疗范围内,但发现凝血因子II、VII、IX和X降低不充分,提示抗凝效果不佳。因此,抗凝方案改为直接口服抗凝剂达比加群。该病例表明,在罕见情况下,尽管活化部分凝血活酶时间(aPTT)正常,但APS患者的INR可能会被人为延长,不能用于监测VKA抗凝治疗。尽管进行了VKA治疗,但怀疑抗凝效果不佳时应促使检测个体凝血因子。